β₂-Adrenergic Agonist Administration and Strength Training

References

• . Price AH, Clissold SP. Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs. 1989;38(1):77–122
   PubMed Web of Science ®Google Scholar
• . Freeman W, Packe GE, Cayton RM. Effect of nebulized salbutamol on maximal exercise performance in men with mild asthma. Thorax. 1989;44(11):942–947
   PubMed Web of Science ®Google Scholar
• . McKenzie DC, Rhodes EC, Stirling DR, . Salbutamol and treadmill performance in non-atopic athletes. Med Sci Sports Exerc. 1983;15(6):520–522
   PubMed Web of Science ®Google Scholar
• . Schmidt A, Diamant B, Bundgaard A, Madsen PL. Ergogenic effect of inhaled beta 2-agonists in asthmatics. Int J Sports Med. 1988;9(5)338–340
   PubMed Web of Science ®Google Scholar
• . Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoreceptor activation. Am J Physiol. 1992;263(1 pt 1):E50–E56
   PubMed Web of Science ®Google Scholar
• . Duncan ND, Williams DA, Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci (Lond). 2000;98(3):339–347
   PubMed Web of Science ®Google Scholar
• . Kim YS, Sainz RD. Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci. 1992;50(6):397–407
   PubMed Web of Science ®Google Scholar
• . Ricks CA, Dalrymple RH, Baker PK, Ingle DL. Use of a β-agonist to alter fat and muscle deposition in steers. J Anim Sci. 1984;59(5):1247–1255
   Web of Science ®Google Scholar
• . Shapland JE, Garner HE, Hatfield DG. Cardiopulmonary effects of clenbuterol in the horse. J Vet Pharmacol Ther. 1981;4(1):43–50
   PubMedGoogle Scholar
• . Strawford A, Barbieri T, Van Loan M, . Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA. 1999;281(14):1282–1290
   PubMed Web of Science ®Google Scholar
• . Sullivan DH, Roberson PK, Johnson LE, . Effects of muscle strength training and testosterone in frail elderly males. Med Sci Sports and Exerc. 2005;37(10):1664–1672
   PubMed Web of Science ®Google Scholar
• . Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci (Lond). 1992;83(5):615–621
   PubMed Web of Science ®Google Scholar
• . Caruso JF, Signorile JF, Perry AC, . The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc. 1995;27(11):1471–1476
   PubMed Web of Science ®Google Scholar
• . Hakkinen K, Komi PV. Effect of different combined concentric and eccentric muscle work regimens on maximal strength development. Journal of Human Movement Studies. 1981;7:33–44
   Google Scholar
• . Jensen K, Di Fabio RP. Evaluation of eccentric exercise in treatment of patellar tendinitis. Phys Ther. 1989;69(3):211–216
   PubMed Web of Science ®Google Scholar
• . Caruso JF, Signorile JF, Perry AC, Clark M, Bamman MM. Time course changes in contractile strength resulting from isokinetic exercise and [beta]2 agonist administration. J Strength Cond Res. 1997;11:8–13
   Web of Science ®Google Scholar
• . Caruso JF, Hamill JL, De Garmo N. Oral albuterol dosing during the latter stages of a resistance exercise program. J Strength Cond Res. 2005;19(1):102–107
   PubMed Web of Science ®Google Scholar
• . Caruso JF, Signorile JF, Clark M, Lowensteyn I, Okuyama T. The effects of chronic administration of β2 agonists upon athletic performance. Journal of the National Strength and Conditioning Association. 1993;15:252
   Google Scholar
• . Maltin CA, Delday MI, Watson JS, . Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Lond). 1993;84(6):651–654
   PubMed Web of Science ®Google Scholar
• . Kinali M, Mercuri E, Main M, . Pilot trial of albuterol in spinal muscular atrophy. Neurology. 2002;59(4):609–610
   PubMed Web of Science ®Google Scholar
• . Kissel JT, McDermott MP, Mendell JR, ; FSH-DY Group. Randomized, double-blind, placebo-controlled trial of albuterol on facioscapulohumeral dystrophy. Neurology. 2001;57(8):1434–1440
   PubMed Web of Science ®Google Scholar
• . Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology. 2008;70(2):137–143
   PubMed Web of Science ®Google Scholar
• . Fowler EG, Graves MC, Wetzel GT, Spencer MJ. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology. 2004;62(6):1006–1008
   PubMed Web of Science ®Google Scholar
• . Signorile JF, Banovac K, Gomez M, Flipse D, Caruso JF, Lowensteyn I. Increased muscle strength in paralyzed patients after spinal cord injury: effect of beta-2 adrenergic agonist. Arch Phys Med Rehab. 1995;76(1)55–58
   PubMed Web of Science ®Google Scholar
• . Dudley GA, Duvoisin MR, Adams GR, Meyer RA, Belew AH, Buchanan P. Adaptations to unilateral lower limb suspension in humans. Aviat Space Environ Med. 1992;63(8):678–683
   PubMedGoogle Scholar
• . Convertino VA, Polet JL, Engelke KA, Hoffler GW, Lane LD, Blomqvist CG. Evidence for increased beta-adrenoreceptor responsiveness induced by 14 days of simulated microgravity in humans. Am J Physiol. 1997;273(1 Pt 2):R93–R99
   Google Scholar
• . Maltin CA, Delday MI, Hay SM, Baillie AG. Denervation increases clenbuterol sensitivity in muscle from young rats. Muscle Nerve. 1992;15(2):188–192
   PubMed Web of Science ®Google Scholar
• . Bowman WC. Effects of adrenergic receptors and inhibitors on the skeletal muscles. In: Szekers L, ed. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag. 1980;54:47–128
   Google Scholar
• . Caruso JF, Hamill JL, Yamauchi M, . Can albuterol help resistance exercise attenuate unloading-induced bone loss? J Strength Cond Res. 2004;18(4):753–759
   PubMed Web of Science ®Google Scholar
• . Caruso JF, Hamill JL, Yamauchi M, Cook TD, Mercado DR, Wickel EE. Albuterol and exercise effects on ankle extensor strength during 40 days of unloading. Aviat Space Environ Med. 2008;79(6):577–584
   PubMedGoogle Scholar
• . Caruso JF, Hamill JL, Yamauchi M, . Albuterol aids resistance exercise in reducing unloading-induced ankle extensor strength losses. J Appl Physiol. 2005;98(5):1705–1711
   PubMed Web of Science ®Google Scholar
• . Caruso JF, Hamill JL, Yamauchi M, Saito K, Cook TD, Mercado DR. Temporal strength changes from resistance exercise and albuterol on unloaded muscle. J Strength Cond Res. 2008;22(4):1156–1163
   PubMed Web of Science ®Google Scholar
• . Caruso JF, Hamill JL, Yamauchi M, . Albuterol helps resistance exercise attenuate unloading-induced knee extensor losses. Aviat Space Environ Med. 2004;75(6):505–511
   PubMedGoogle Scholar
• . Moore NG, Pegg GG, Sillence MN. Anabolic effects of the beta 2-adrenoceptor agonist salmeterol are dependent on route of administration. Am J Physiol. 1994;267(3 pt 1):E475–E484
   Google Scholar
• . Babij P, Booth FW. Clenbuterol prevents or inhibits loss of specific mRNAs in atrophying rat skeletal muscle. Am J Physiol. 1988;254(5 pt 1):C657–C660
   PubMed Web of Science ®Google Scholar
• . Deshaies Y, Willemot J, Le Blanc J. Protein synthesis, amino acid uptake, and pools during isoproterenol-induced hypertrophy of the rat heart and tibialis muscle. Can J Physiol Pharmacol. 1981;59(2):113–121
   PubMed Web of Science ®Google Scholar
• . Emery PW, Rothwell NJ, Stock MJ, Winter PD. Chronic effects of beta 2- adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep. 1984;4(1):83–91
   PubMed Web of Science ®Google Scholar
• . Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. Am J Physiol. 1988;254(6 pt 1):E726–E732
   PubMedGoogle Scholar
• . Carter WJ, Lynch ME. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metabolism. 1994;43(9):1119–1125
   PubMed Web of Science ®Google Scholar
• . Dodd SL, Powers SK, Vrabas IS, Criswell D, Stetson S, Hussain R. Effects of clenbuterol on contractile and biochemical properties of skeletal muscle. Med Sci Sports Exerc. 1996;28(6):669–676
   PubMed Web of Science ®Google Scholar
• . Li JB, Jefferson LS. Effect of isoproterenol on amino acid levels and protein turnover in skeletal muscle. Am J Physiol. 1977;232(2):E243–E249
   Google Scholar
• . Reeds PJ, Hay SM, Dorwood PM, Palmer RM. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. Br J Nutr. 1986;56(1):249–258
   PubMed Web of Science ®Google Scholar
• . Costelli P, García-Martínez C, Llovera M, . Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest. 1995;95(5):2367–2372
   PubMed Web of Science ®Google Scholar
• . Navegantes LC, Resano NM, Migliorini RH, Kettelhut IC. Catecholamines inhibit Ca(2+)-dependent proteolysis in rat skeletal muscle through beta(2)-andrenoceptors and cAMP. Am J Physiol Endocrinol Metab. 2001;281(3): E449–E454
   Web of Science ®Google Scholar
• . Lynch GS, Hayes A, Campbell SP, Williams DA. Effects of beta2-agonist administration and exercise on contractile activation of skeletal muscle fibers. J Appl Physiol. 1996;81(4):1610–1618
   PubMed Web of Science ®Google Scholar
• . Maltin CA, Reeds PJ, Delday MI, Hay SM, Smith FG, Lobley GB. Inhibition and reversal of denervation-induced atrophy by the beta-agonist growth promoter, clenbuterol. Biosci Rep. 1986;6(9):811–818
   PubMed Web of Science ®Google Scholar
• . Ricart-Firinga C, Stevens L, Canu MH, Nemirovskaya TL, Mounier Y. Effects of beta(2)-agonist clenbuterol on biochemical and contractile properties of unloaded soleus fibers of rat. Am J Physiol Cell Physiol. 2000;278(3):C582–C588
   Web of Science ®Google Scholar
• . Clarke MS, Caldwell RW, Feeback DL. Modulation of sarcoplasmic reticulum cholesterol content during mechanical unloading-induced muscle atrophy. Human Space Symposium Proceedings. 2000;13:241–244
   Google Scholar
• . Larsson S. Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration. Acta Med Scand Suppl. 1977;608:1–40
   PubMedGoogle Scholar
• . Cockcroft JR, Gazis AG, Cross DJ, . Beta(2)-adrenoreceptor polymorphism determines vascular reactivity in humans. Hypertension. 2000;36(3):371–375
   PubMed Web of Science ®Google Scholar
• . Cullum VA, Farmer JB, Jack D, Levy GP. Salbutamol: a new, selective beta-adrenoreceptive receptor stimulant. Br J Pharmacol. 1969;35(1):141–151
   PubMed Web of Science ®Google Scholar
• . Larsson S, Svedmyr N. Tremor caused by sympathomimetics is mediated by beta2-adrenoreceptors. Scand J Respir Dis. 1977;58(1):5–10
   PubMedGoogle Scholar
• . Goldstein DA, Tan YK, Soldin SJ. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Eur J Clin Pharmacol. 1987;32(6):631–634
   PubMed Web of Science ®Google Scholar
• . Morgan DJ. Clinical pharmacokinetics of beta-agonists. Clin Pharmacokinet. 1990;18(4):270–294
   PubMed Web of Science ®Google Scholar
• . World Anti-Doping Agency. 2008 Prohibited List: International Standard. September 22, 2007
   Google Scholar